English 
Chronic Kidney Disease (CKD) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00
Growth of the Prevalence CKD population will contribute to increasing sales in the CKD therapy market over our forecast period. An estimated annual growth rate of 0.4% in the Prevalent CKD population across the major pharmaceutical markets will contribute to increasing CKD therapy sales. In 2019, there were approximately 94 million prevalent cases of CKD in the major markets; we expect the number of cases will exceed 2.08 million in 2032 owing to changes in population demographics and increasing cases of CKD associated conditions such as anemia, hyperphosphatemia, secondary hyperthyroidism, diabetes kidney disease and cardiovascular patients group.
The continuous involvement of supportive treatments including renal replacement therapies for the management of dialysis dependent CKD patients will contribute to the the overall growth of the CKD therapy market. We forecast that total sales of the total current RRTs market will reach more than $13 billion by 2032.
Description
Chronic kidney disease (CKD) is a major emerging global public health problem affecting over 94 million people in G7 countries (United States, EU5 and Japan) and over 850 million people and is currently one of the most common diseases in the world. The large number of comorbidities accompanying CKD, the large number of prescribed medications, poor mental health, the high hospitalization rate, and the high mortality rate demonstrate that the patient complexity of CKD is enormous and has exceeded all other medical specialties when nine complexity markers were assessed. Although significant progress has been made in understanding the causes of kidney disease and the factors driving progression to end-stage renal disease, clinical decision support systems that tailor individual patient therapy can reduce the risk of progression and may be used to monitor and modify therapy in individual CKD patients
Chronic Kidney Disease –CKD Epidemiology
In the United States, approximately 10% of cases are on peritoneal dialysis and 60% on hemodialysis. With transplantation currently accounting for approximately 30% and home hemodialysis (HD) accounting for 2% of patients, the use of peritoneal dialysis (PD) will need to significantly increase from its current rate of ~ 10% to approach this high goal.
Chronic Kidney Disease–CKD Market Forecast
Report Highlights
- Chronic Kidney Disease–CKD Current Market Trends
- Chronic Kidney Disease–CKD Current & Forecasted Cases across the G7 Countries
- Chronic Kidney Disease–CKD Market Opportunities And Sales Potential for Agents
- Chronic Kidney Disease–CKD Patient-based Market Forecast to 2032
- Chronic Kidney Disease–CKD Untapped Business Opportunities
- Chronic Kidney Disease–CKD Product Positioning Vis-a-vis Competitors’ Products
- Chronic Kidney Disease–CKD KOLs Insight
Additional information
| Price | 2-3 User License, Enterprise License, Single User License, Site License |
|---|
Table of Contents
- Chronic Kidney Disease Disease Background
- Chronic Kidney Disease Definition
- Symptoms
- Risk Factor
- Diagnosis
- Advancing American Kidney Health (AAKH) Initiatives
- Epidemiology Estimated and Forecast to 2032
- Epidemiology Research Method & Data Sources Used
- Prevalent Cases of Chronic Kidney Disease in the United States 2022-2032
- Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in the United States 2022-2032
- Prevalent Cases of Chronic Kidney Disease in Germany 2022-2032
- Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in Germany 2022-2032
- Prevalent Cases of Chronic Kidney Disease in France 2022-2032
- Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in France 2022-2032
- Prevalent Cases of Chronic Kidney Disease in Italy 2022-2032
- Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in Italy 2022-2032
- Prevalent Cases of Chronic Kidney Disease in Spain 2022-2032
- Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in Spain 2022-2032
- Prevalent of Chronic Kidney Disease in the United Kingdom 2022-2032
- Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in the United Kingdom 2022-2032
- Prevalent Cases of Chronic Kidney Disease in Japan 2022-2032
- Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in Japan 2022-2032
- Epidemiology Research Method & Data Sources Used
- Patients on Dialysis per country
- Patients on Dialysis per country by Treatment Modality
- Current Unmet Needs in Chronic Kidney Disease
- Current Treatment Paradigm
- Treatment guidelines for Chronic Kidney Disease
- Current Approved Treatments for CKD
- Reimbursement Scenario in Chronic Kidney Disease
- Dialysis modality distribution
- Global Reimbursement of Different Dialysis Strategies
- Reimbursement by Self-care hemodialysis, Home hemodialysis, CAPD, APD & Hospital hemodialysis
- Reimbursement Scenarios in the Belgium, Germany, The Netherlands, United Kingdom, France, United States & Ontario, Canada, Japan and Other countries.
- Primary Findings
- Emerging Therapies Chapters
- daprodustat (GSK)
- Canagliflozin (J&J/Mitsubishi Tanabe Pharma )
- darbepoetin alfa (Kissei Pharma/ JCR Pharma)
- ferumoxytol (AMAG Pharmaceuticals)
- Roxadustat (FibroGen/ Astellas Pharma)
- vadadustat (Akebia Therapeutics)
- Tenapanor (Ardelyx)
- Bardoxolone methyl (Reata Pharmaceuticals, Inc)
- Dapagliflozin (AstraZeneca)
- Empagliflozin (Boehringer Ingelheim/ Eli Lilly)
- TRC-101 (Tricida Inc.)
- PDprotec (Zytoprotec)
- Total Market Forecast
- Key Summary Findings
- G7 total Market for Chronic Kidney Disease 2022-2032 (USD Million)
- G7 total Market for Chronic Kidney Disease by Therapies 2022-2032 (USD Million)
- Key Summary Findings
- Market Forecast by Country
- United States
- United States Market for Chronic Kidney Disease 2022-2032 (USD Million)
- United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2022-2032 (USD Million)
- Germany
- Germany Market for Chronic Kidney Disease 2022-2032 (USD Million)
- United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2022-2032 (USD Million)
- France
- France Market for Chronic Kidney Disease 2022-2032 (USD Million)
- United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2022-2032 (USD Million)
- Italy
- Italy Market for Chronic Kidney Disease 2022-2032 (USD Million)
- United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2022-2032 (USD Million)
- Spain
- Spain Market for Chronic Kidney Disease 2022-2032 (USD Million)
- United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2022-2032 (USD Million)
- United Kingdom
- United Kingdom Market for Chronic Kidney Disease 2022-2032 (USD Million)
- United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2022-2032 (USD Million)
- Japan
- Japan Market for Chronic Kidney Disease 2022-2032 (USD Million)
- United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2022-2032 (USD Million)
- United States
- Market Drivers & Barriers
Sample Enquiry
Related products
-
Metastatic Renal cell carcinoma (mRCC) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCurrently, tyrosine kinase inhibitors (TKIs) and anti-VEGF antibodies are widely used in first- and second-line treatments for mRCC. Despite the current treatments, there remains the unmet need for early diagnosis and treatment options. Emerging drugs in development like Dovitinib (Allarity Therapeutics) and Savolitinib/ AZD6094 (Astrazeneca), and others will expand the first-line and second-line settings for patients with mRCC and likely to address the current unmet needs for the treatment of mRCC. The upcoming treatment options for mRCC can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments.
-
Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCorticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). Current Corticobasal syndrome (CBS) treatment is limited to levodopa, commonly prescribed medication for the treatment of Parkinson’s disease. Thus, there is a huge unmet need for a medical treatment to improve the quality of life. Emerging therapies like Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals) have the potential to overcome the treatment barrier. Corticobasal syndrome market size will reflect high growth from 2025-2030 due to launch of Fausdil (Woolsey) in the market from 2025 year.
-
Central Precocious Puberty | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the diagnosed CPP population will contribute to increasing sales in the CPP therapy market over our forecast period. An estimated annual growth rate of 0.12% in the diagnosed CPP population across the major pharmaceutical markets will contribute to increasing CPP therapy sales. In 2022, there were approximately xx diagnosed cases of CPP in the major markets; we expect the number of cases will exceed xx in 2032 owing to changes in population demographics and increasing awareness related to this rare disease.Strong Uptake of the 6-months Leuprolide acetate (Fensolvi) will be driven by the need for an alternative therapy for 3-months depot Leuprolide acetate and will contribute to the growth of the CPP market. We expect leuprolide acetate to be preferentially prescribed to patients. However, as physicians become more familiar with the agent, we expect Fensolvi to gain more patient share. The drug is forecasted to earn sales of $xx million in 2032. -
Adult Acute Lymphoblastic Leukemia (aALL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsAbout 60% of ALL adult patients relapse or are refractory to first-line therapy and a high unmet need continues to exist. CD19 CAR T candidate with compelling activity and safety profile and has the potential to change the standard of care as a curative therapy for r / r ALL. Sales of emerging therapies to treat adult Acute Lymphoblastic Leukemia (aALL) in the countries under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2022-2032 study period, adding an estimated value to a total more than $1 billion market by 2032